[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amgen Inc (AMGN)

Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 238,061,904
  • Shares Outstanding, K 540,632
  • Annual Sales, $ 36,751 M
  • Annual Income, $ 7,711 M
  • EBIT $ 11,426 M
  • EBITDA $ 17,793 M
  • 60-Month Beta 0.41
  • Price/Sales 6.51
  • Price/Cash Flow 13.08
  • Price/Book 20.46

Options Overview Details

View History
  • Implied Volatility 29.76% (-0.26%)
  • Historical Volatility 26.11%
  • IV Percentile 69%
  • IV Rank 53.96%
  • IV High 37.59% on 07/28/26
  • IV Low 20.58% on 08/28/25
  • Expected Move (DTE 1) 11.92 (2.72%)
  • Put/Call Vol Ratio 1.40
  • Today's Volume 4,425
  • Volume Avg (30-Day) 12,570
  • Put/Call OI Ratio 1.27
  • Today's Open Interest 142,797
  • Open Int (30-Day) 127,927
  • Expected Range 426.78 to 450.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 35 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $5.69
  • Number of Estimates 9
  • High Estimate $6.04
  • Low Estimate $5.48
  • Prior Year $5.64
  • Growth Rate Est. (year over year) +0.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
375.96 +16.56%
on 08/03/26
447.03 -1.97%
on 08/25/26
+61.97 (+16.47%)
since 07/27/26
3-Month
322.30 +35.97%
on 06/02/26
447.03 -1.97%
on 08/25/26
+102.17 (+30.40%)
since 05/27/26
52-Week
269.77 +62.45%
on 09/26/25
447.03 -1.97%
on 08/25/26
+150.26 (+52.18%)
since 08/27/25

Most Recent Stories

More News
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52

AMGN : 438.13 (-0.50%)
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky

1 Unpopular Stock That Should Get More Attention and 2 We Find Risky

ADT : 7.45 (+0.13%)
TSLX : 18.67 (-0.80%)
AMGN : 438.13 (-0.50%)
2 Reasons to Like AMGN (and 1 Not So Much)

2 Reasons to Like AMGN (and 1 Not So Much)

AMGN : 438.13 (-0.50%)
3 Market-Beating Stocks with Exciting Potential

3 Market-Beating Stocks with Exciting Potential

ARES : 142.88 (+0.63%)
AMGN : 438.13 (-0.50%)
ATRO : 77.82 (+0.40%)
2 Momentum Stocks Worth Investigating and 1 We Avoid

2 Momentum Stocks Worth Investigating and 1 We Avoid

UCB : 35.17 (-0.14%)
TILE : 37.88 (-2.12%)
AMGN : 438.13 (-0.50%)
Amgen’s Q2 Earnings Call: Our Top 5 Analyst Questions

Amgen’s Q2 Earnings Call: Our Top 5 Analyst Questions

AMGN : 438.13 (-0.50%)
Stock Indices Fall from Early Highs and Settle Mixed

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -0.17%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.83%. September...

AMAT : 475.81 (-0.82%)
B : 47.39 (+0.83%)
ANET : 200.07 (-1.08%)
HL : 21.33 (+3.04%)
CDE : 22.19 (+3.50%)
TXN : 265.16 (+1.30%)
$IUXX : 29,507.75 (+0.97%)
AMGN : 438.13 (-0.50%)
ZNU26 : 108-190 (-0.06%)
SHOP : 153.41 (+2.08%)
COMP : 11.10 (-2.46%)
ESU26 : 7,726.00 (+0.47%)
Why Amgen (AMGN) Stock Is Trading Up Today

Why Amgen (AMGN) Stock Is Trading Up Today

AMGN : 438.13 (-0.50%)
Stocks Supported by Stellar Earnings

The S&P 500 Index ($SPX ) (SPY ) today is up +0.31%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.03%. September E-mini S&P futures...

AMAT : 475.81 (-0.82%)
B : 47.39 (+0.83%)
ANET : 200.07 (-1.08%)
HL : 21.33 (+3.04%)
CDE : 22.19 (+3.50%)
WYNN : 95.00 (-2.23%)
TXN : 265.16 (+1.30%)
$IUXX : 29,507.75 (+0.97%)
AMGN : 438.13 (-0.50%)
ZNU26 : 108-190 (-0.06%)
SHOP : 153.41 (+2.08%)
COMP : 11.10 (-2.46%)
Strong Earnings Push the S&P 500 to New Record High

The S&P 500 Index ($SPX ) (SPY ) today is up +0.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.74%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.51%. September E-mini S&P futures...

B : 47.39 (+0.83%)
ANET : 200.07 (-1.08%)
HL : 21.33 (+3.04%)
CDE : 22.19 (+3.50%)
WYNN : 95.00 (-2.23%)
$IUXX : 29,507.75 (+0.97%)
AMGN : 438.13 (-0.50%)
ZNU26 : 108-190 (-0.06%)
SHOP : 153.41 (+2.08%)
COMP : 11.10 (-2.46%)
ESU26 : 7,726.00 (+0.47%)
CDW : 146.69 (+3.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 447.38
2nd Resistance Point 445.13
1st Resistance Point 442.74
Last Price 438.13
1st Support Level 438.09
2nd Support Level 435.84
3rd Support Level 433.45

See More

52-Week High 447.03
Last Price 438.13
Fibonacci 61.8% 379.32
Fibonacci 50% 358.40
Fibonacci 38.2% 337.48
52-Week Low 269.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.